Antiplatelet therapy in stroke prevention: Present and future

Cerebrovascular Diseases

Volumn 21, Issue SUPPL. 1, 2006, Pages 1-6

  Caplan, Louis R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Abciximab; Aspirin; Cilostazol; Clopidogrel; Dipyridamole; GP IIb IIIa inhibitors; Ticlopidine

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HEPARINOID; HERBACEOUS AGENT; HIRUDIN; IBUPROFEN; ICOSAPENTAENOIC ACID; INDOMETACIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PHENYLBUTAZONE; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; WARFARIN; XIMELAGATRAN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM; FIBRIN CLOT; FUNGUS; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; LOW DRUG DOSE; NEUTROPENIA; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RASH; REVIEW; STROKE; THROMBOCYTE AGGLUTINATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; TREE;

ASPIRIN; BLOOD PLATELETS; CEREBROVASCULAR ACCIDENT; DIPYRIDAMOLE; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; TICLOPIDINE;

EID: 32844455423     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090356     Document Type: Review

References (73)

1. Fields WS, Lemak NA: A History of Stroke: Its Recognition and Treatment. New York, Oxford University Press, 1989, pp 115-119.
2. Craven LL: Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J 1953;75:38-44.
3. Craven LL: Prevention of coronary and cerebral thrombosis. Miss Valley Med J 1956;78:213-215.
4. Mundall J, Quintero P, von Kaulla K, et al: Transient monocular blindness and increased platelet aggregability treated with aspirin - A case report. Neurology 1972;22:280-285.
5. Harrison MJG, Marshall J, Meadows JC, et al: Effect of aspirin in amaurosis fugax. Lancet 1971;ii:743-744.
6. Fields WS, Lemak N, Frankowski R, et al: Controlled trial of aspirin in cerebral ischemia. Stroke 1977;8:301-306.
7. Barnett HJM: The Canadian Cooperative Study: a randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53-59.
8. Caplan LR: Brain embolism; in Caplan LR, Hurst JW, Chimowitz MB (eds): Clinical Neurocardiology. New York, Dekker, 1999.
9. Fisher CM, Ojemann RG: A clinico-pathologic study of carotid endarterectomy plaques. Rev Neurol (Paris) 1986;142:573-589.
10. Heistad DD: Unstable coronary-artery plaques. N Engl J Med 2003;349:2285-2287.
11. Amarenco P, Duyckaerts C, Tzourio C, et al: The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med 1992;326:221-225.
12. Mustard JF, Murphy EA, Rowsell HC, et al: Factors influencing thrombus formations in vivo. Am J Med 1962;33:621-647.
13. Libman E, Sacks B: A hitherto undescribed form of valvular and mural endocarditis. Arch Int Med 1924;33:701-737.
14. Klemperer P, Pollack AD, Baehr G: Pathology of disseminated lupus erythematosis. Arch Pathol 1941;32:569-631.
15. Baehr G, Klemperer P, Schifrin A: A diffuse disease of the peripheral circulation (usually associated with lupus erythematosis and endocarditis). Am J Med 1952;13:591-596.
16. Brenner B, Blumenfeld Z, Markiewicz W, Reisner SA: Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol 1991;18:931-936.
17. Kooiker JC, MacLean JM, Sumi SM: Cerebral embolism, marantic endocarditis, and cancer. Arch Neurol 1976;33:260-264.
18. Edoute Y, Haim N, Rinkevich D, Brenner B, Reisner SA: Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients. Am J Med 1997;102:252-258.
19. Amico L, Caplan LR, Thomas C: Cerebrovascular complications of mucinous cancer. Neurology 1989;39:522-526.
20. Weksler B: Antithrombotic therapies in the management of cerebral ischemia; in Plum F, Pulsinelli W (eds): Cerebrovascular Diseases: Proceedings of the Fourteenth Princeton Conference. New York, Raven Press, 1985, pp 211-223.
21. Deykin D: Thrombogenesis. N Engl J Med 1967;276:622-628.
22. Caplan LR: Caplan's Stroke: A Clinical Approach, ed 3. Boston, Butterworth-Heinemann, 2000.
23. Moncada S, Vane J: Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl J Med 1979;300:1142-1147.
24. Nurden AT: Platelet function and pharmacology of antiplatelet drugs. Cerebrovasc Dis 1997;7(suppl 6):2-9.
25. Moncada C: Biologic and therapeutic potential of prostacyclin. Stroke 1983;14:157-168.
26. 2 after low dose aspirin. N Engl J Med 1981;304:76-79.
27. Weksler B, Pelt S, Alonso D, et al: Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983;308:800-805.
28. UK-TIA Study Group: United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J (Clin Res Ed) 1988;296:316-320.
29. The SALT Collaborative Group: Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991;338:1345-1349.
30. The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor stroke. N Engl J Med 1991;325:1261-1266.
31. Helgason CM, Hoff JA, Kondos GT, Brace LD: Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. Stroke 1993;24:1458-1461.
32. Helgason CM, Tortorice L, Winkler S, et al: Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-350.
33. Ticlopidine. Lancet 1991;337:459-460.
34. Sharis PJ, Cannon CP, Loscalzo J: The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998;129:394-405.
35. Ono S, Ashida S, Abiko Y: Hemorheological effect of ticlopidine in the rat. Thromb Res 1983;31:549-556.
36. Hass WK, Easton JD, Adams HP, et al: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507.
37. Gent M, Easton JD, Hachinski V, et al: The Canadian American Ticlopinine Study (CATS) in thromboembolic stroke. Lancet 1989;i:1215-1220.
38. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al: Thrombotic thrombocytopenic purpura associated with ticlopidine. A report of 60 cases. Ann Intern Med 1998;128:541-544.
39. Weksler B: Antiplatelet agents in stroke prevention. Cerebrovasc Dis 2000;10(suppl 5):41-48.
40. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 1996;348:1329-1339.
41. Diener HC, Bogousslavsky J, Brass LM, et al; on behalf of the MATCH investigators: Aspirin and clopidogrel vs clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 2004;364:331-337.
42. Hankey GJ, Eikelboom JW: Adding aspirin to clopidogrel after TIA and ischemic stroke. Benefits do not match risks. Neurology 2005;64:1117-1121.
43. Fitzgerald GA: Dipyridamole. N Engl J Med 1987;316:1247-1257.
44. Honour A, Hockaday T, Mann J: The synergistic effect of aspirin and dipyridamole upon platelet thrombi in living blood vessels. Br J Exp Pathol 1977;58:268-272.
45. Fields WS, Yatsu F, Conomy J, et al: Persantine-aspirin trial in cerebral ischemia: the American-Canadian Cooperative Study group. Stroke 1983;14:97-103.
46. Bousser MG, Eschwege E, Hagenah M, et al: 'AICLA' controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983;14:5-14.
47. ESPS Group: European Stroke Prevention Study (ESPS): principal endpoints. Lancet 1987;ii:1351-1354.
48. Diener HC, Cunha L, Forbes C, et al: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
49. Leonardi-Bee J, Bath PMW, Bousser MG, et al: Dipyridamole for preventing recurrent ischemic stroke and other vascular events. A metaanalysis of individual patient data from randomized controlled trials. Stroke 2005;36:162-168.
50. Sacco RL, Sivenius J, Diener H-C: Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol 2005;62:403-408.
51. Ikeda Y, Kikuchi M, Murakami H: Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid, and ticlopidine on platelet function ex vivo: randomized, double-blind cross-over study. Arzneimittelforschung 1987;37:563-566.
52. Tanaka K, Ishikawa T, Hagiwara M, et al: Effects of cilostazol, a selective camp phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology 1988;36:313-320.
53. Gotoh F, Tohgi H, Hirai S, et al: Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9:147-157.
54. Kwon SU, Cho YJ, Koo J-S, et al: Cilostazol prevents the progression of the symptomatic intracranial stenosis. The multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005;36:782-786.
55. Tcheng JE: Differences among the parenteral glycoprotein IIb/IIIa inhibitors and implications for treatment. Am J Cardiol 1999;83:7E-15E.
56. Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
57. Wallace RC, Furlan AJ, Moliterno DJ, et al: Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIb/IIIa receptor inhibitor. AJNR Am J Neuroradiol 1997;18:1257-1260.
58. Abciximab in Acute Ischemic Stroke Investigators: Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled dose-escalation study. Stroke 2000;31:601-609.
59. Coller BS: Anti-GpIIb/IIIa drugs: current status and future directions. Thromb Haemost 2001;86:427-443.
60. Dyerberg J, Bang HO, Stoffersen E, et al: Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. Lancet 1978;ii:17-119.
61. Radack K, Deck C, Huster G: Dietary supplementation with low-dose fish oils lowers fibrinogen levels: a randomized double-blind controlled study. Ann Int Med 1989;111:757-758.
62. Kobayashi S, Hirai A, Terano T, et al: Reduction in blood viscosity by eicosapentaenoic acid. Lancet 1981;ii:197.
63. Grotta J, Ackerman R, Correia J, et al: Whole-blood viscosity parameters and cerebral blood flow. Stroke 1982;13:296-298.
64. Thomas D: Whole blood viscosity and cerebral blood flow. Stroke 1982;13:285-287.
65. Drouet L: Fibrinogen, a treatable risk factor? Cerebrovasc Dis 1996;6:2-6.
66. Kannel WB: Influence of fibrinogen on cardiovascular disease. Drugs 1997;54(suppl 3):32-40.
67. Rothwell PM, Howard SC, Power DA, et al: Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5,113 patients with transient ischemic attack and minor stroke. Stroke 2004;35:2300-2305.
68. Kee DB Jr, Wood JH: Influence of blood rheology on cerebral circulation; in Wood JH (ed): Cerebral Blood Flow: Physiological and Clinical Aspects. New York, McGraw-Hill, 1987, pp 173-185.
69. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB: Fibrinogen and risk of cardiovascular disease. JAMA 1987;258:1183-1186.
70. Lowe G, Rumley A, Norrie J, et al: Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost 2000;84:553-558.
71. Smith FB, Lee AJ, Fowkes GR, Price JF, Rumley A, Lowe GDO: Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb 1997;17:3321-3325.
72. Tanne D, Benderly M, Goldbourt U, et al; for the Bezafibrate Infarction Prevention Study Group: A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the Bezafibrate Infarction Prevention Study. Am J Med 2001;111:457-463.
73. Wannamethee SG, Lowe GDO, Whincup PH, Rumley A, Walker M, Lennon L: Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002;105:1785-1790.